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INTRODUCTION:  The  GatekeeperTM is the most  recent  bulking  agent  used  in the  treatment  of fecal  incon-
tinence  with  no reported  complications.  This  case  reports  side effects  similar  to  other  bulking  agents,
namely  migration  of  the  prosthesis  and  perianal  abscess.
PRESENTATION  OF  CASE:  A 52 year  old  gentleman  presented  with  a  history  of  fecal  soiling.  He  underwent
uncomplicated  surgery  in  2012  for  6 GatekeeperTM implantations  with  only  temporary  improvements.  In
2013,  endorectal  ultrasound  revealed  prosthesis  migration.  In  2014,  he  presented  with  a perianal  abscess
which  contained  one  of  the  prosthesis.
DISCUSSION:  The  GatekeeperTM, made  of  the  inert  Hyexpan,  typically  implanted  in  the intersphinctericulking agents region,  has  been  used  for the  treatment  of  fecal  incontinence  since  its discontinuation  in  the  treatment
of  gastroesophageal  reﬂux  disease.5 The  GatekeeperTM was  implemented  on  a small  number  of  subjects
for  which  the  typical  side  effects  of bulking  agents  were  not  seen.
CONCLUSION:  Larger  studies  need  to  be conducted  to investigate  the  advantages  or  perhaps  disadvantages
of  the  GatekeeperTM over  other  bulking  agents.
©  2014  The  Authors.  Published  by  Elsevier  Ltd. on behalf  of Surgical  Associates  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
Fecal incontinence can negatively affect a person’s lifestyle in
any ways, if not greatly psychological. The incidence has been
ifﬁcult to acquire as the majority of people suffering from fecal
ncontinence are reluctant to get medical help. It has been sug-
ested that between 2%1 and 7% of the general population suffer
rom fecal incontinence but this is deﬁnitely a much lower per-
entage of the population than actually exists.
The GatekeeperTM, one of the latest agents used for the improve-
ent or perhaps even treatment of fecal incontinence, has been
amed the “novel”2 bulking agent. With only two studies currently
vailable on the GatekeeperTM,2,3 it was concluded that it was  the
ideal’ bulking agent for many reasons including the fact that it
as no known complications as of yet and in addition, maintains
edium to long term results, unlike other agents.
Almost everything has complications. Clearly, more research is
eeded, and, for complications to be picked up by the radar, a bigger
opulation needs to be studied.
. Case presentationA 52 year old Arab gentleman presented complaining of pas-
ive soiling since 2007 which mainly occurred post defecation. He
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would have more than 10 episodes per week; however, he did
not need to wear pads. He had no complaints of urinary incon-
tinence, sexual dysfunction, constipation or any complaints of
sensing incomplete evacuation at the time of presentation. The
Cleveland Clinic incontinence score4 was  4.
The patient is a known case of bipolar disorder diagnosed over 5
years ago, on Lithium, and has a past history of L5-S1 disc prolapse
since 2002 for which microdiscectomy was done in 2008. He had
no history of other surgeries or history of pelvic trauma.
In 2007, he was followed up by the urology team for voiding
problems but when he attended the surgical clinic in 2009, the
voiding issues were resolved. He was examined and advised phys-
iotherapy as his anal sphincter tone was  normal and no underlying
pathologies were found; colonoscopy was unremarkable.
When the patient was  reviewed again in 2010, it was diagnosed
that he had a long anal canal, which was the basis of his fecal soiling.
No intervention was  planned apart from continued physiotherapy.
In 2012 he was reviewed again, still he was  symptomatic and
did not improve with physiotherapy. He underwent surgery for the
GatekeeperTM implantation; 6 implants were inserted at 1, 3, 5, 7,
9 and 11 o’clock positions. There were no complications during the
implantation process. Post operatively he was  advised to take rest
for 1 week and to avoid any physical exercise for another 3 weeks.
He was  reviewed 3 months post operatively and some improve-
ments were noted with regard to the soiling which had decrease
to 3 episodes per week. The Cleveland Clinic score4 was then 3.
One year post operatively, the patient reported that the frequency
of soiling had returned to more than 10 episodes per week as
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Fig. 1. Endorectal ultrasound showing the migrating gatekeepers.
as initially. Endorectal ultrasound was done and revealed the
igration of the bulking agents from the intersphincteric region
Figs. 1 and 2).
In 2014, he presented with perianal pain and swelling and
as diagnosed to have a perianal abscess, for which incision and
rainage was done and one of the gatekeeper prosthesis popped
ut of the abscess cavity (Fig. 3).
. Discussion
The GatekeeperTM was ﬁrst used in the treatment of gastro-
sophageal reﬂux disease.5 After its use was discontinued, the
atekeeperTM was implemented for the treatment of fecal incon-
inence. However, being an agent of the new generation of bulking
gents, not enough subjects were studied to record side effects; andFig. 2. Migrated Gatekeeper near the prostate level.Fig. 3. Gatekeeper prosthesis obtained from incision site of perianal abscess.
of the few subjects that were operated on, no complications were
found in the medium and long term follow ups.
The GatekeeperTM is made of HYEXPANTM (polyacrylonitrile), an
inert and durable material that is implanted in the intersphincteric
region and over time absorbs water and expands to the appropriate
shape, size and consistency to act as an ideal bulking agent. The
intersphincteric placement was  preferred in order to reduce the
risk of ﬁstulas, ulcers or migration to other parts of the body as any
foreign body would.
Generally, the complications of bulking agents include6: ecchy-
mosis, inﬂammation, anal ulceration, perianal abscess, and sepsis.
They may  also include general symptoms like abdominal pain, post-
operative proctalgia, fever, diarrhea and constipation.
4. Conclusion
Numerous trials have been carried out using various types
of bulking agents but regrettably none of them have been able
to maintain their success rates over long periods of time. The
GatekeeperTM was  assumed to have done the trick – solving all the
problems that other bulking agents had. However, with not many
studies done on the product, it had not revealed its side effects.
Unfortunately, in this particular case, regardless of the inter-
sphincteric placement of the prosthesis, migration had occurred
along with the formation of a perianal abscess later on.
Larger studies and longer follow ups are needed to understand
the possible side effects of the GatekeeperTM more deeply.
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Key learning points
• The bulking agents in treating fecal incontinence did not prove to be effective.
• The GatekeeperTM which was assumed to solve the problems and side effects of the other bulking agents unfortunately
has the same problems.
• It acts as a foreign body with subsequent risk of infection and ﬁstula formation.
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